selected scholarly activity
-
conferences
- Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial. Journal of Clinical Oncology. 2024
- Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER). Cancer Research. 2022
- The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.. Journal of Clinical Oncology. e23142-e23142. 2019
- Assessment of myocardial injury early after initiation of treatment in breast cancer patients using the Beckman Coulter and Abbott Diagnostics high-sensitivity cardiac troponin I tests. Clinical Biochemistry. 56-57. 2018
- Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects). International Journal of Radiation Oncology Biology Physics. S88-S89. 2018
- Adenomyoepithelioma with carcinoma of the breast: case report with next generation sequencing. Virchows Archiv. S52-S52. 2018
- Evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.. Journal of Clinical Oncology. e18548-e18548. 2018
- Abstract P5-20-17: Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study. Cancer Research. p5-20-17-p5-20-17. 2018
- Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study. Cancer Research. 2018
- Code status communication training in Canadian postgraduate oncology programs: A needs assessment survey.. Journal of Clinical Oncology. 13-13. 2017
- The PULSES project: Teaching the vital elements of code status discussions to oncology residents.. Journal of Clinical Oncology. 46-46. 2017
- Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC). Cancer Research. CT131-CT131. 2017
- Rates of trastuzumab-associated cardiotoxicity in patients with HER2-positive breast cancer at a tertiary cancer centre.. Journal of Clinical Oncology. e12030-e12030. 2017
- The PULSES project: Teaching the vital elements of code status discussions to oncology residents.. Journal of Clinical Oncology. 10024-10024. 2017
- Abstract 3787: Thyroid hormone induced proliferation of breast cancer cell lines: A novel approach to hormone therapy. Cancer Research. 3787-3787. 2016
- Expression of the CD200 tolerance signaling molecule and its receptor (CD200R1) in normal and malignant trophoblasts. Journal of Reproductive Immunology. 30-31. 2015
- Abstract 1154: Serum and urine markers of metabolic dysfunction in colorectal cancer: A pilot study. Cancer Research. 1154-1154. 2015
- Blood and urine markers of metabolic dysfunction in colorectal cancer: a pilot study.. Journal of Clinical Oncology. e14611-e14611. 2015
- Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC). Journal of Clinical Oncology. 2015
- Assessment of galectin-3, N-terminal pro-brain natriuretic peptide and inflammatory cytokines in patients with myocardial injury after initiation of adjuvant trastuzumab therapy. Clinical Biochemistry. 1144-1144. 2014
- PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)based chemotherapy (CT).. Journal of Clinical Oncology. 2014
- Prognostic potential of thyroid receptor TRα2 in breast cancer.. Journal of Clinical Oncology. e11535-e11535. 2014
- Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.. Journal of Clinical Oncology. 2013
- Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.. Journal of Clinical Oncology. e20522-e20522. 2013
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 2012
- Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC).. Journal of Clinical Oncology. 2012
- Chromosome 17 Polysomy and Monosomy as Predictive Markers of Complete Pathological Response (pCR) in Women with Locally Advanced Breast Cancer (LABC). Modern Pathology. 36A-36A. 2012
- Chromosome 17 Polysomy and Monosomy as Predictive Markers of Complete Pathological Response (pCR) in Women with Locally Advanced Breast Cancer (LABC). Laboratory Investigation. 36A-36A. 2012
- NT-proBNP measurement using a multiplex platform in cancer and chest pain populations. Clinical Biochemistry. 1172-1172. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 2011
- HER2/neu Testing in Breast Carcinoma. Concordance Study Fluorescent In Situ Hybridization (FISH) vs. Chromogenic In Situ Hybridization (CISH). Modern Pathology. 38A-38A. 2009
- HER2/neu Testing in Breast Carcinoma. Concordance Study Fluorescent In Situ Hybridization (FISH) vs. Chromogenic In Situ Hybridization (CISH). Laboratory Investigation. 38A-38A. 2009
- Value of Chemotherapy with ECF in Advanced Esophageal Cancer Treated with Endoscopic Guided High Dose Rate Intraluminal Brachytherapy (EGHDRILBT). International Journal of Radiation Oncology Biology Physics. S267-S267. 2008
- Generalizability of results from oncology clinical trials: Toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 6633-6633. 2008
- Patterns of adjuvant systemic therapy in elderly with breast cancer (BC). Journal of Clinical Oncology. 11597-11597. 2008
- Tertiary center breast cancer pathology review: Positive impact on patient care. Laboratory Investigation. 30A-30A. 2007
- Phase II pilot study on brachytherapy with ECF vs brachytherapy and standard chemoradiation in esophageal cancer. Annals of Oncology. VII90-VII91. 2007
- 2177. International Journal of Radiation Oncology Biology Physics. S308-S308. 2006
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases. Journal of Clinical Oncology. 3198-3198. 2005
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases.. Journal of Clinical Oncology. 240S-240S. 2005
-
internet publications
-
journal articles
- Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.. Journal of the National Cancer Institute. 117:889-897. 2025
- Concentrations and agreement over 10 years with different assay versions and analyzers for troponin T and N-terminal pro-B-type natriuretic peptide.. Clinical Chemistry and Laboratory Medicine. 63:e121-e123. 2025
- A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer. Breast Cancer Research and Treatment. 208:523-533. 2024
- Patient and Provider Attitudes and Preferences Regarding Early Palliative Care Delivery for Patients with Advanced Gastrointestinal Cancers: A Prospective Survey. Current Oncology. 31:3329-3341. 2024
- Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.. Journal of Clinical Oncology. 42:515-515. 2024
- Abstract PO4-13-01: A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes. Cancer Research. 84. 2024
- The Significance of Thyroid Hormone Receptors in Breast Cancer: A Hypothesis-Generating Narrative Review. Current Oncology. 31:2364-2375. 2024
- High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population. JACC: CardioOncology. 6:136-138. 2024
- Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab. Oncologist. 28:e712-e722. 2023
- Detection of Macrotroponin in Patients Receiving Treatment for Breast Cancer. CJC OPEN. 5:658-660. 2023
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007). Cancer Research. 83. 2023
- Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC). Cancer Research. 83. 2023
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of Clinical Oncology. 40:787-800. 2022
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine. 385:2336-2347. 2021
- Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. CJC OPEN. 3:1372-1382. 2021
- Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. iScience. 24:102619-102619. 2021
- Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Cancer Research. 81:gs3-00-gs3-00. 2021
- Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. Journal of Bone Oncology. 26:100343-100343. 2021
- Code Status Communication Training in Postgraduate Oncology Programs: A Needs Assessment. Current Oncology. 27:607-613. 2020
- Code Status Communication Training in Postgraduate Oncology Programs: A Needs Assessment.. Current Oncology. 27:607-613. 2020
- Breaking silence: a survey of barriers to goals of care discussions from the perspective of oncology practitioners. BMC Cancer. 19:130. 2019
- Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?. Oncologist. 24:1405-1409. 2019
- Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists. Breast Journal. 25:1222-1224. 2019
- Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity. JACC: CardioOncology. 1:1-10. 2019
- A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. Clinica Chimica Acta. 495:355-357. 2019
- An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction. Current Oncology. 26:240-246. 2019
- MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. Clinical Oncology. 31:479-485. 2019
- Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab. Canadian Journal of Cardiology. 35:545.e1-545.e2. 2019
- Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. Breast Cancer Research and Treatment. 171:709-717. 2018
- Soluble CD200 in secretory phase endometriosis endometrial venules may explain endometriosis pathophysiology and provide a novel treatment target. Journal of Reproductive Immunology. 129:59-67. 2018
- Human Papillomavirus Status and Esophageal Adenocarcinoma. JAMA network open. 1:e181415-e181415. 2018
- Clinical Practice Guidelines in Breast Cancer. Current Oncology. 25:151-160. 2018
- Role of allied health care professionals in goals-of-care discussions with hospitalized patients and perceived barriers: a cross-sectional survey. CMAJ open. 6:E241-E247. 2018
- A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. Breast Cancer Research and Treatment. 167:485-493. 2018
- Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 13:e0209486-e0209486. 2018
- Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology. 35:3978-3986. 2017
- Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. Breast Cancer Research. 19:76. 2017
- Reply to T.J. Powles et al. Journal of Clinical Oncology. 35:2720-2721. 2017
-
Changes in expression of the
CD 200 tolerance‐signaling molecule and its receptor (CD 200R) by villus trophoblasts during first trimester missed abortion and in chronic histiocytic intervillositis. American Journal of Reproductive Immunology. 78. 2017 - Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 35:2062-2081. 2017
- Uptake of a 21-Gene Expression Assay in Breast Cancer Practice: Views of Academic and Community-Based Oncologists. Current Oncology. 24:138-145. 2017
- Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer. Journal of Gastrointestinal Oncology. 8:32-38. 2017
- Targeted metabolomics in colorectal cancer: a strategic approach using standardized laboratory tests of the blood and urine. Hypoxic Signaling. Volume 5:61-66. 2017
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. Journal of Clinical Oncology. 34:3914-3920. 2016
- Corrigendum to “The CD200 tolerance-signaling molecule and its receptor, CD200R1, are expressed in human placental villus trophoblast and in peri-implant decidua by 5 weeks’ gestation” [J. Reprod. Immunol. 112 (2015) 20–23]. Journal of Reproductive Immunology. 117:89-90. 2016
- Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment. 157:109-116. 2016
- The CD200 tolerance-signaling molecule and its receptor, CD200R1, are expressed in human placental villus trophoblast and in peri-implant decidua by 5 weeks’ gestation. Journal of Reproductive Immunology. 112:20-23. 2015
-
The Receptor for the
CD 200 Tolerance‐Signaling Molecule Associated with Successful Pregnancy is Expressed by Early‐Stage Breast Cancer Cells in 80% of Patients and by Term Placental Trophoblasts. American Journal of Reproductive Immunology. 74:387-391. 2015 - Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 33:e12082-e12082. 2015
- 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. British Journal of Cancer. 112:1737-1743. 2015
- Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. Breast Cancer Research and Treatment. 149:293-301. 2015
- Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. Clinical Biochemistry. 47:155-157. 2014
- The CD200-tolerance Signaling Molecule Associated with Pregnancy Success is Present In Patients with Early-stage Breast Cancer but Does not Favor Nodal Metastasis. American Journal of Reproductive Immunology. 72:435-439. 2014
- PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).. Journal of Clinical Oncology. 32:4022-4022. 2014
- Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy. Clinical Chemistry. 59:327-329. 2013
- Cancer Care Ontario Guideline Recommendations for Hormone Receptor Testing in Breast Cancer. Clinical Oncology. 24:684-696. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 30:6049-6049. 2012
- Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC).. Journal of Clinical Oncology. 30:e14001-e14001. 2012
- Is Colon Cancer Survival Influenced by Tumor Location?. Journal of Clinical Oncology. 30:1732-1733. 2012
- Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?. Journal of Clinical Oncology. 30:1408-1410. 2012
- Systematic Review on Hormone Receptor Testing in Breast Cancer. Applied Immunohistochemistry and Molecular Morphology. 20:214-263. 2012
- Chemotherapy for colorectal cancer. The Lancet Oncology. 13:e3-e4. 2012
- Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—An update from the Canadian society of clinical chemists (CSCC). Clinical Biochemistry. 44:1273-1277. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 29:7018-7018. 2011
- Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population. Journal of Clinical Oncology. 29:e177-e177. 2011
- Generalizability of Toxicity Data from Oncology Clinical Trials to Clinical Practice: Toxicity of Irinotecan-Based Regimens in Patients with Metastatic Colorectal Cancer. Current Oncology. 16:13-20. 2009
- Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CANADIAN MEDICAL ASSOCIATION JOURNAL. 172:1319-1320. 2005
- Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines. Current Oncology. 9:7-12. 2002